A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 2, 2001, Pages 116-123

  Ungsedhapand, Chaiwat ^a   Kroon, Eugene D M B ^a,b   Suwanagool, Surapol ^c   Ruxrungtham, Kiat ^a,d   Yimsuan, Nongluk ^a   Sonjai, Areerat ^c   Ubolyam, Sasiwimol ^a,d   Buranapraditkun, Supranee ^d   Tiengrim, Surapee ^c   Pakker, Nadine ^b   Kunanusont, Chaiyos ^e   Lange, Joep M A ^b   Cooper, David A ^f   Phanuphak, Praphan ^a,d  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MAHIDOL UNIVERSITY   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral treatment naive; Didanosine; HIV; Lamivudine; Triple nucleoside reverse transcriptase inhibitor therapy; Zidovudine

Indexed keywords

DIDANOSINE; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND; VIRUS LOAD; VOMITING;

EID: 0035363844     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200106010-00003     Document Type: Article

References (22)

1. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Antiretroviral therapy: Where are we?
5. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: The Inter-Company Collaboration Protocol
6. Sanctuary sites in HIV-1 infection
7. Pharmacological considerations in antiretroviral therapy
8. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection
9. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
10. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
11. A pilot study of low-dose zidovudine in human immunodeficiency virus infection
12. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome
13. A randomized trial of reduced doses of azidothymidine in Japanese patients with human immunodeficiency virus type 1 infection
14. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
15. 3
16. Comparison of antiviral response with abacavir/Combivir to indinavir/Combivir in therapy-naïve adults at 48 weeks (CNA3005)
17. The Atlantic Study: A randomised, open-labeled trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, final 48 week data
18. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naïve patients
19. Evolution of medical services for HIV/AIDS in Thailand
20. Formulating rational use of antiretrovirals in Thailand
21. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
22. Hit HIV-1 hard, but only when necessary